跳转至内容
Merck
CN

GF15415691

foil, 100x100mm, thickness 0.1mm, as rolled, 99%

别名:

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
La
CAS号:
分子量:
138.91
MDL编号:
UNSPSC代码:
12141607
PubChem化学物质编号:
NACRES:
NA.23

方案

99%

表单

foil

制造商/商品名称

Goodfellow 154-156-91

电阻率

54 μΩ-cm

尺寸 × 厚度

100 x 100 mm × 0.1 mm

沸点

3464 °C (lit.)

mp

920 °C (lit.)

密度

6.19 g/mL at 25 °C (lit.)

SMILES字符串

[La]

InChI

1S/La

InChI key

FZLIPJUXYLNCLC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

For updated SDS information please visit www.goodfellow.com.

法律信息

Product of Goodfellow

储存分类代码

4.3 - Hazardous materials which set free flammable gases upon contact with water

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Monique P Curran et al.
Drugs, 69(16), 2329-2349 (2009-10-27)
Orally administered lanthanum carbonate (Fosrenol) dissociates in the acid environment of the upper gastrointestinal tract to release the cation lanthanum, which then binds dietary phosphate. Lanthanum carbonate was effective in reducing levels of serum phosphate and serum calcium x phosphate
Yongsheng Yang et al.
Molecular pharmaceutics, 10(2), 544-550 (2012-12-20)
A conventional human pharmacokinetic (PK) in vivo study is often considered as the "gold standard" to determine bioequivalence (BE) of drug products. However, this BE approach is not always applicable to the products not intended to be delivered into the
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Tilman B Drüeke
Seminars in dialysis, 20(4), 329-332 (2007-07-20)
Controlling serum phosphorus levels in patients with renal failure is critical. The use of oral phosphate-binding agents is universal for patients with end-stage kidney disease to reduce phosphate absorption. The therapeutic goal is to reduce serum phosphorus levels without disturbing
M Cozzolino et al.
The International journal of artificial organs, 30(4), 293-300 (2007-05-24)
Phosphate overload is a dramatic consequence in end-stage renal disease (ESRD) patients. Recent studies have well documented that abnormalities in mineral and bone metabolism in these patients are associated with increased cardiovascular morbidity and mortality. Elevated serum phosphate and calcium-phosphate

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门